GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (XSWX:RLF) » Definitions » Debt-to-Asset

Relief Therapeutics Holding (XSWX:RLF) Debt-to-Asset : 0.03 (As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Relief Therapeutics Holding Debt-to-Asset?

Relief Therapeutics Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was CHF0.40 Mil. Relief Therapeutics Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was CHF2.02 Mil. Relief Therapeutics Holding's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was CHF70.92 Mil. Relief Therapeutics Holding's debt to asset for the quarter that ended in Jun. 2024 was 0.03.


Relief Therapeutics Holding Debt-to-Asset Historical Data

The historical data trend for Relief Therapeutics Holding's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Debt-to-Asset Chart

Relief Therapeutics Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 - 0.01 0.02 0.04

Relief Therapeutics Holding Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.02 0.03 0.04 0.03

Competitive Comparison of Relief Therapeutics Holding's Debt-to-Asset

For the Biotechnology subindustry, Relief Therapeutics Holding's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relief Therapeutics Holding's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's Debt-to-Asset falls into.



Relief Therapeutics Holding Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Relief Therapeutics Holding's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Relief Therapeutics Holding's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Relief Therapeutics Holding  (XSWX:RLF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Relief Therapeutics Holding Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Relief Therapeutics Holding Business Description

Traded in Other Exchanges
Address
Avenue de Secheron 15, Geneva, CHE, 1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.

Relief Therapeutics Holding Headlines

No Headlines